SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Lossos, I. S. Articles by Levy, R. Search for Related Content PubMed PubMed Citation Articles by Lossos, I. S. Articles by Levy, R. Related Collections Neoplasia Clinical Trials and Observations Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 August 2001, Vol. 98, No. 4, pp. 945-951 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma Izidore S. Lossos, Carol D. Jones, Roger Warnke, Yasodha Natkunam, Herbert Kaizer, James L. Zehnder, Rob Tibshirani, and Ronald Levy From the Departments of Medicine, Pathology, and Health Research and Policy, Division of Oncology, Stanford University Medical Center, CA. Diffuse large B-cell lymphoma (DLBCL) is characterized by a marked degree of morphologic and clinical heterogeneity. Establishment of parameters that can predict outcome could help to identify patients who may benefit from risk-adjusted therapies. BCL-6 is a proto-oncogene commonly implicated in DLBCL pathogenesis. A real-time reverse transcription-polymerase chain reaction assay was established for accurate and reproducible determination of BCL-6 mRNA expression. The method was applied to evaluate the prognostic significance of BCL-6 expression in DLBCL. BCL-6 mRNA expression was assessed in tumor specimens obtained at the time of diagnosis from 22 patients with primary DLBCL. All patients were subsequently treated with anthracycline-based chemotherapy regimens. These patients could be divided into 2 DLBCL subgroups, one with high BCL-6 gene expression whose median overall survival (OS) time was 171 months and the other with low BCL-6 gene expression whose median OS was 24 months (P = .007). BCL-6 gene expression also predicted OS in an independent validation set of 39 patients with primary DLBCL (P = .01). BCL-6 protein expression, assessed by immunohistochemistry, also predicted longer OS in patients with DLBCL. BCL-6 gene expression was an independent survival predicting factor in multivariate analysis together with the elements of the International Prognostic Index (IPI) (P = .038). By contrast, the aggregate IPI score did not add further prognostic information to the patients' stratification by BCL-6 gene expression. High BCL-6 mRNA expression should be considered a new favorable prognostic factor in DLBCL and should be used in the stratification and the design of risk-adjusted therapies for patients with DLBCL. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: Immunoglobulin (Ig)/BCL6 versus non-Ig/BCL6 gene fusion in diffuse large B-cell lymphoma corresponds to a high- versus low-level expression of BCL6 mRNA Chiyoko Ueda, Takashi Uchiyama, and Hitoshi Ohno Blood 2002 99: 2624-2625. [Full Text] [PDF] This article has been cited by other articles: H.-W. Bernd, M. Ziepert, C. Thorns, W. Klapper, H.-H. Wacker, M. Hummel, H. Stein, M.-L. Hansmann, G. Ott, A. Rosenwald, et al. Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials Haematologica, November 1, 2009; 94(11): 1569 - 1580. [Abstract] [Full Text] [PDF] L. M. Morton, M. P. Purdue, T. Zheng, S. S. Wang, B. Armstrong, Y. Zhang, I. Menashe, N. Chatterjee, S. Davis, Q. Lan, et al. Risk of Non-Hodgkin Lymphoma Associated with Germline Variation in Genes that Regulate the Cell Cycle, Apoptosis, and Lymphocyte Development Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1259 - 1270. [Abstract] [Full Text] [PDF] D de Jong, W Xie, A Rosenwald, M Chhanabhai, P Gaulard, W Klapper, A Lee, B Sander, C Thorns, E Campo, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium) J. Clin. Pathol., February 1, 2009; 62(2): 128 - 138. [Abstract] [Full Text] [PDF] D. Ennishi, K. Takeuchi, M. Yokoyama, H. Asai, Y. Mishima, Y. Terui, S. Takahashi, H. Komatsu, K. Ikeda, M. Yamaguchi, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy Ann. Onc., November 1, 2008; 19(11): 1921 - 1926. [Abstract] [Full Text] [PDF] S. Le Gouill, P. Talmant, C. Touzeau, A. Moreau, R. Garand, N. Juge-Morineau, F. Gaillard, T. Gastinne, N. Milpied, P. Moreau, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement Haematologica, October 1, 2007; 92(10): 1335 - 1342. [Abstract] [Full Text] [PDF] J. R. Pollack A Perspective on DNA Microarrays in Pathology Research and Practice Am. J. Pathol., August 1, 2007; 171(2): 375 - 385. [Abstract] [Full Text] [PDF] H. Nyman, M. Adde, M.-L. Karjalainen-Lindsberg, M. Taskinen, M. Berglund, R.-M. Amini, C. Blomqvist, G. Enblad, and S. Leppa Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy Blood, June 1, 2007; 109(11): 4930 - 4935. [Abstract] [Full Text] [PDF] H Veelken, S Vik Dannheim, J Schulte Moenting, U. Martens, J Finke, and A Schmitt-Graeff Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy Ann. Onc., May 1, 2007; 18(5): 931 - 939. [Abstract] [Full Text] [PDF] D. de Jong, A. Rosenwald, M. Chhanabhai, P. Gaulard, W. Klapper, A. Lee, B. Sander, C. Thorns, E. Campo, T. Molina, et al. Immunohistochemical Prognostic Markers in Diffuse Large B-Cell Lymphoma: Validation of Tissue Microarray As a Prerequisite for Broad Clinical Applications--A Study From the Lunenburg Lymphoma Biomarker Consortium J. Clin. Oncol., March 1, 2007; 25(7): 805 - 812. [Abstract] [Full Text] [PDF] L. H. Sehn, B. Berry, M. Chhanabhai, C. Fitzgerald, K. Gill, P. Hoskins, R. Klasa, K. J. Savage, T. Shenkier, J. Sutherland, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP Blood, March 1, 2007; 109(5): 1857 - 1861. [Abstract] [Full Text] [PDF] J. C van Galen, J. J F Muris, J. J Oudejans, W. Vos, C. P E Giroth, G. J Ossenkoppele, A. P Otte, F. M Raaphorst, and C. J L M Meijer Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCL J. Clin. Pathol., February 1, 2007; 60(2): 167 - 172. [Abstract] [Full Text] [PDF] Y.-W. Chen, X.-T. Hu, A. C. Liang, W.-Y. Au, C.-C. So, M. L. Wong, L. Shen, Q. Tao, K.-M. Chu, Y.-L. Kwong, et al. High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma Blood, October 1, 2006; 108(7): 2373 - 2383. [Abstract] [Full Text] [PDF] G. W. van Imhoff, E.-J. G. Boerma, B. van der Holt, E. Schuuring, L. F. Verdonck, H. C. Kluin-Nelemans, and P. M. Kluin Prognostic Impact of Germinal Center-Associated Proteins and Chromosomal Breakpoints in Poor-Risk Diffuse Large B-Cell Lymphoma J. Clin. Oncol., September 1, 2006; 24(25): 4135 - 4142. [Abstract] [Full Text] [PDF] D. J. Wallace, D. Shen, G. F. Reed, M. Miyanaga, M. Mochizuki, H. N. Sen, S. S. Dahr, R. R. Buggage, R. B. Nussenblatt, and C.-C. Chan Detection of the bcl-2 t(14;18) Translocation and Proto-Oncogene Expression in Primary Intraocular Lymphoma. Invest. Ophthalmol. Vis. Sci., July 1, 2006; 47(7): 2750 - 2756. [Abstract] [Full Text] [PDF] L. Kaderali, T. Zander, U. Faigle, J. Wolf, J. L. Schultze, and R. Schrader CASPAR: a hierarchical bayesian approach to predict survival times in cancer from gene expression data Bioinformatics, June 15, 2006; 22(12): 1495 - 1502. [Abstract] [Full Text] [PDF] D. Schenten, A. Egert, M. Pasparakis, and K. Rajewsky M17, a gene specific for germinal center (GC) B cells and a prognostic marker for GC B-cell lymphomas, is dispensable for the GC reaction in mice Blood, June 15, 2006; 107(12): 4849 - 4856. [Abstract] [Full Text] [PDF] C. Moskowitz Is it time to stop treating subsets of DLBCL with R-CHOP? Blood, June 1, 2006; 107(11): 4197 - 4198. [Full Text] [PDF] J. N. Winter, E. A. Weller, S. J. Horning, M. Krajewska, D. Variakojis, T. M. Habermann, R. I. Fisher, P. J. Kurtin, W. R. Macon, M. Chhanabhai, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study Blood, June 1, 2006; 107(11): 4207 - 4213. [Abstract] [Full Text] [PDF] I. Oschlies, W. Klapper, M. Zimmermann, M. Krams, H.-H. Wacker, B. Burkhardt, L. Harder, R. Siebert, A. Reiter, and R. Parwaresch Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial Blood, May 15, 2006; 107(10): 4047 - 4052. [Abstract] [Full Text] [PDF] T. Batchelor and J. S. Loeffler Primary CNS Lymphoma J. Clin. Oncol., March 10, 2006; 24(8): 1281 - 1288. [Abstract] [Full Text] [PDF] I. S. Lossos and D. Morgensztern Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma J. Clin. Oncol., February 20, 2006; 24(6): 995 - 1007. [Abstract] [Full Text] [PDF] J.-F. Garcia, J.-F. Garcia, L. Maestre, E. Lucas, L. Sanchez-Verde, S. Romero-Chala, M.-A. Piris, and G. Roncador Genetic Immunization: A New Monoclonal Antibody for the Detection of BCL-6 Protein in Paraffin Sections J. Histochem. Cytochem., January 1, 2006; 54(1): 31 - 38. [Abstract] [Full Text] [PDF] E. Sakane-Ishikawa, S.-i. Nakatsuka, Y. Tomita, S. Fujita, I. Nakamichi, T. Takakuwa, H. Sugiyama, S. Fukuhara, M. Hino, A. Kanamaru, et al. Prognostic Significance of BACH2 Expression in Diffuse Large B-Cell Lymphoma: A Study of the Osaka Lymphoma Study Group J. Clin. Oncol., November 1, 2005; 23(31): 8012 - 8017. [Abstract] [Full Text] [PDF] I. S. Lossos Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma J. Clin. Oncol., September 10, 2005; 23(26): 6351 - 6357. [Abstract] [Full Text] [PDF] A K H Shia, G-G Gan, S Jairaman, and S-C Peh High frequency of germinal centre derivation in diffuse large B cell lymphoma from Asian patients J. Clin. Pathol., September 1, 2005; 58(9): 962 - 967. [Abstract] [Full Text] [PDF] C. Hoffmann, M. Tiemann, C. Schrader, D. Janssen, E. Wolf, M. Vierbuchen, R. Parwaresch, K. Ernestus, A. Plettenberg, A. Stoehr, et al. AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping Blood, September 1, 2005; 106(5): 1762 - 1769. [Abstract] [Full Text] [PDF] M. M. Quigley Showing the way: large cell lymphoma Blood, April 1, 2005; 105(7): 2624 - 2624. [Full Text] [PDF] X. Lu, H. Nechushtan, F. Ding, M. F. Rosado, R. Singal, A. A. Alizadeh, and I. S. Lossos Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas Blood, April 1, 2005; 105(7): 2924 - 2932. [Abstract] [Full Text] [PDF] Z. Li, X. Wang, R. Y.-L. Yu, B. B. Ding, J. J. Yu, X.-M. Dai, A. Naganuma, E. R. Stanley, and B. H. Ye BCL-6 Negatively Regulates Expression of the NF-{kappa}B1 p105/p50 Subunit J. Immunol., January 1, 2005; 174(1): 205 - 214. [Abstract] [Full Text] [PDF] I. S. Lossos, D. K. Czerwinski, A. A. Alizadeh, M. A. Wechser, R. Tibshirani, D. Botstein, and R. Levy Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes N. Engl. J. Med., April 29, 2004; 350(18): 1828 - 1837. [Abstract] [Full Text] [PDF] C. P. Hans, D. D. Weisenburger, T. C. Greiner, R. D. Gascoyne, J. Delabie, G. Ott, H. K. Muller-Hermelink, E. Campo, R. M. Braziel, E. S. Jaffe, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Blood, January 1, 2004; 103(1): 275 - 282. [Abstract] [Full Text] [PDF] G. Z. Ferl, J. M. Timmerman, and O. N. Witte From the Cover: Extending the utility of gene profiling data by bridging microarray platforms PNAS, September 16, 2003; 100(19): 10585 - 10587. [Full Text] [PDF] K. M. Braaten, R. A. Betensky, L. de Leval, Y. Okada, F. H. Hochberg, D. N. Louis, N. L. Harris, and T. T. Batchelor BCL-6 Expression Predicts Improved Survival in Patients with Primary Central Nervous System Lymphoma Clin. Cancer Res., March 1, 2003; 9(3): 1063 - 1069. [Abstract] [Full Text] [PDF] I. S. Lossos, A. A. Alizadeh, R. Rajapaksa, R. Tibshirani, and R. Levy HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma Blood, January 15, 2003; 101(2): 433 - 440. [Abstract] [Full Text] [PDF] L. Colomo, A. Lopez-Guillermo, M. Perales, S. Rives, A. Martinez, F. Bosch, D. Colomer, B. Falini, E. Montserrat, and E. Campo Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma Blood, January 1, 2003; 101(1): 78 - 84. [Abstract] [Full Text] [PDF] J. K. Erban and Z. Tang Case 38-2002 - A 54-Year-Old Man with Hypercalcemia, Renal Dysfunction, and an Enlarged Liver N. Engl. J. Med., December 12, 2002; 347(24): 1952 - 1960. [Full Text] [PDF] X. Wang, Z. Li, A. Naganuma, and B. H. Ye Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas PNAS, November 12, 2002; 99(23): 15018 - 15023. [Abstract] [Full Text] [PDF] M. Kurata, Y. Maesako, C. Ueda, M. Nishikori, T. Akasaka, T. Uchiyama, and H. Ohno Characterization of t(3;6)(q27;p21) Breakpoints in B-Cell Non-Hodgkin's Lymphoma and Construction of the Histone H4/BCL6 Fusion Gene, Leading to Altered Expression of Bcl-6 Cancer Res., November 1, 2002; 62(21): 6224 - 6230. [Abstract] [Full Text] [PDF] T. T.-L. Tang, D. Dowbenko, A. Jackson, L. Toney, D. A. Lewin, A. L. Dent, and L. A. Lasky The Forkhead Transcription Factor AFX Activates Apoptosis by Induction of the BCL-6 Transcriptional Repressor J. Biol. Chem., April 12, 2002; 277(16): 14255 - 14265. [Abstract] [Full Text] [PDF] M.-J. Artiga, A.-I. Saez, C. Romero, M. Sanchez-Beato, M.-S. Mateo, C. Navas, M. Mollejo, and M. A. Piris A Short Mutational Hot Spot in the First Intron of BCL-6 Is Associated with Increased BCL-6 Expression and with Longer Overall Survival in Large B-Cell Lymphomas Am. J. Pathol., April 1, 2002; 160(4): 1371 - 1380. [Abstract] [Full Text] [PDF] C. Ueda, T. Uchiyama, and H. Ohno Immunoglobulin (Ig)/BCL6 versus non-Ig/BCL6 gene fusion in diffuse large B-cell lymphoma corresponds to a high- versus low-level expression of BCL6 mRNA Blood, April 1, 2002; 99(7): 2624 - 2625. [Full Text] [PDF] S. L. Barrans, I. Carter, R. G. Owen, F. E. Davies, R. D. Patmore, A. P. Haynes, G. J. Morgan, and A. S. Jack Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma Blood, February 15, 2002; 99(4): 1136 - 1143. [Abstract] [Full Text] [PDF] J. M. Connors, E. D. Hsi, and F. M. Foss Lymphoma of the Skin Hematology, January 1, 2002; 2002(1): 263 - 282. [Abstract] [Full Text]

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020